pseudoephedrine hydrochloride(redirected from Drixoral Nasal Decongestant)
Pharmacologic class: Sympathomimetic
Therapeutic class: Decongestant (systemic)
Pregnancy risk category C
Stimulates alpha-adrenergic receptors, causing vasoconstriction of respiratory tract; relaxes bronchial smooth muscle through beta2-adrenergic stimulation
Capsules: 60 mg
Capsules (extended-release): 120 mg, 240 mg
Capsules (soft gel): 30 mg
Oral solution: 15 mg/5 ml, 30 mg/5 ml
Syrup: 30 mg/5 ml
Tablets: 30 mg, 60 mg
Tablets (chewable): 15 mg
Tablets (extended-release): 120 mg, 240 mg
Tablets (extended-release, film-coated): 120 mg
Indications and dosages
➣ Nasal, sinus, or eustachian tube congestion
Adults and children ages 12 and older: 60 mg P.O. q 4 to 6 hours p.r.n. (not to exceed 240 mg/day); or 120 mg (extended-release) q 12 hours or 240 mg (extended-release) q 24 hours
• Hypersensitivity to drug or other sympathomimetics
• Alcohol intolerance (with some liquid products)
• Severe coronary artery disease
• MAO inhibitor use within past 14 days
• Children younger than age 12 (extended-release forms)
Use cautiously in:
• hyperthyroidism, diabetes mellitus, prostatic hypertrophy, ischemic heart disease, glaucoma
• elderly patients (more sensitive to drug's CNS effects)
• pregnant or breastfeeding patients.
• Give at least 2 hours before bedtime to minimize insomnia.
CNS: anxiety, nervousness, dizziness, drowsiness, excitability, fear, hallucinations, headache, insomnia, restlessness, asthenia, seizures
CV: palpitations, hypertension, tachycardia, cardiovascular collapse
GI: anorexia, dry mouth
Respiratory: respiratory difficulty
Drug-drug. Beta-adrenergic blockers: increased pressor effects of pseudoephedrine
MAO inhibitors: hypertensive crisis
Mecamylamine, methyldopa, reserpine: decreased antihypertensive effect of these drugs
Other sympathomimetics: additive effects, greater risk of toxicity
Drug-food. Foods that acidify urine: decreased drug efficacy
Foods that alkalize urine: increased drug efficacy
• Monitor vital signs.
• Assess neurologic and cardiovascular status regularly.
• Advise patient to take at least 2 hours before bedtime to reduce insomnia.
• Tell patient not to crush or break extended-release tablets or capsules.
• Advise patient to discontinue use and consult prescriber if he experiences nervousness, dizziness, or insomnia.
• Tell patient to consult prescriber before taking other over-the-counter products.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.